摘要
目的:观察两厂产的二甲双胍与阿卡波糖联合治疗2型糖尿病的疗效和用药费用,并进行成本-效果分析,从而指导临床更合理选择和应用药物。方法:将符合2型糖尿病诊断的患者84例分为A组和B组各42例,A组给予合资厂的二甲双胍(中美上海施贵宝制药有限公司)0.5g,tid,餐前1/2h服用,阿卡波糖(德国拜耳制药有限公司)50mg,tid,餐前即服;B组给予国产的二甲双胍(贵州天安药业股份有限公司)0.5g,tid,餐前1/2h服用,阿卡波糖50mg,tid,餐前即服。结果:A、B治疗组的有效率分别为85.7%和80.9%,两组无统计学意义(P>0.05);A、B治疗组的总药费分别为370.8元和268.2元;有效率每增加一个百分点,B组比A组节省101.2元。结论:在两组治疗效果无显著性差异情况下,B组的治疗成本最低,是一种经济有效的治疗方案。
OBJECTIVE： To observe the efficacy and costs of mefformin （from two manufacturers） in combination with acarbose in the treatment of Type Ⅱ diabetes mellitus and to conduct a cost-effectiveness analysis so as to guide the rational use and choice of these drugs in the clinic. METHODS： A total of 84 cases who were diagnosed as having type Ⅱ diabetes mellitus were enrolled： 42 （Group A） were assigned to receive metformin （SASS, a joint venture in Shanghai） 0.5 g tid 1/ 2h before meal plus acarbose （Bayer AG, German） 50mg tid just before meal, another 42 （control group） to receive home- made mefformin （Guizhou Tian＇an Pharmaceutical Co., Ltd. ） 0.5 g tid 1/2h before meal plus acarbose 50rag tid just before meal. RESULTS： The effective rate of group A vs. group B was 85.7 % vs. 80.9 %, showing no significant differences between two groups （ P 〉 0.05）. The total cost of group A vs. group B was 370.8 yuan vs. 268.2 yuan ; for every percent of increment of the effective rate, the cost of group B was 101.2 yuan less than in group A. CONCLUSION： Under the condition of no significant differences between two groups, the cost of group B was lower, and it is a more economical and effective scheme.
出处
《中国医院用药评价与分析》
2007年第3期220-221,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
糖尿病
两厂产的二甲双胍
阿卡波糖
成本-效果分析
Diabetes mellitus
Metformin from two manufactures
Acarbose
Cost-effectiveness analysis
